-
WhatsApp
!
     

, - /
    • ->
  • , -
(, ) / CoDiovan, Co-Diovan (valsartan, hydrochlorothiazide)
(, ) / CoDiovan, Co-Diovan (valsartan, hydrochlorothiazide)
., / 160 /12,5 / 98 .
Novartis Pharma

    24527 .
!
( ) / CoDiovan, Co-Diovan (Valsartan + hydrochlorothiazide)
( ) / CoDiovan, Co-Diovan (Valsartan + hydrochlorothiazide)
. / 80 + 12,5 / 98 .
Novartis Pharma

    22617 .
!
(, ) / Co-Diovan, CoDiovan Forte (valsartan, hydrochlorothiazide)
(, ) / Co-Diovan, CoDiovan Forte (valsartan, hydrochlorothiazide)
. / 320 /25 / 98 .
Novartis Pharma

    37895 .
!
(, ) / Co-Diovan, CoDiovan Forte (valsartan, hydrochlorothiazide)
(, ) / Co-Diovan, CoDiovan Forte (valsartan, hydrochlorothiazide)
. / 160 /25 / 98 .
Novartis Pharma

    29238 .
!
100 / MEXICOR
100 / MEXICOR
. 100 / 20 .

 !
() / MICARDIS (Telmisartan) 40
() / MICARDIS (Telmisartan) 40
. 40 / 98 .
Boehringer Ingelheim

    20371 .
!
/ ROSUVASTATIN Hexal
/ ROSUVASTATIN Hexal
., /. ., 5 / 30 .
Hexal AG

    3434 .
!
/ ROSUVASTATIN Hexal
/ ROSUVASTATIN Hexal
., /. ., 40 / 30 .
Hexal AG

    4991 .
!
/ ROSUVASTATIN Hexal
/ ROSUVASTATIN Hexal
., /. ., 10 / 30 .
Hexal AG

    4163 .
!
/ ROSUVASTATIN Hexal
/ ROSUVASTATIN Hexal
., /. ., 10 / 30 .
Hexal AG

    3685 .
!
0 | 10 | 20 | 30 | 40 | 50 ...



, .
, , .
, ,

01 2026
:
, . , .
25 2026
:
. .
( ) / NOVAMINSULFON (Metamizole)
( ) / NOVAMINSULFON (Metamizole)
/ 500 /, . 50 / 1 .
| 3919 .
!
( ) / NOVAMINSULFON (Metamizole)
() / SYNACTHEN (Tetracosactide)
- / DAPSON-FATOL
() / LONOLOX (minoxidil)
, ( ) / CAPHOSOL (saline)
() / KEPPRA (levetiracetam)
() / KEPPRA (levetiracetam)
() / KEPPRA (levetiracetam)
() / OBSIDAN (Propranolol)
ГЕМАНГИОЛ (Пропранолол) / HEMANGIOL, HEMANGEOL (Propranolol)
/ BRANOLIND N
() / BENTELAN (Betamethasone)
( ) / BREVACTID (Chorionic gonadotropin)
() - / PETNIDAN (Ethosuximide)
() / WOBENZYM immun (Tripsina)
3 ( ) / HUMULIN M3 (insulin human)
() / SELENCIN (homeopathic)
() / GYNOKADIN gel (Estradiolvalerat)
() / IRUXOL N (Chloramphenicol) 30
() / DAIVONEX (calcipotriol)
/
2010-2024 . .